2023

Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer’s disease spectrum

Authors:

Dauar, M. T., Labonté, A., Picard, C., Miron, J., Rosa-Neto, P., Zetterberg, H., Blennow, K., Villeneuve, S., & Poirier, J.

Journal:

Alzheimer's & Dementia

Abstract

Introduction: We investigate the CNTN5 rs1461684 G variant and the contactin 5 protein in sporadic Alzheimer’s disease (sAD).

Methods: Contactin 5, sAD biomarkers, and synaptic markers were measured in the cerebrospinal fluid (CSF). Amyloid and tau deposition were assessed using positron emission tomography. Contactin 5 protein and mRNA levels were measured in brain tissue.

Results: CSF contactin 5 increases progressively in cognitively unimpaired individuals and is decreased in mild cognitive impairment and sAD. CSF contactin 5 correlates with sAD biomarkers and with synaptic markers. The rs1461684 G variant associates with faster disease progression in cognitively unimpaired subjects. Cortical full-length and isoform 3 CNTN5 mRNAs are decreased in the presence of the G allele and as a function of Consortium to Establish a Registry for Alzheimer’s Disease stages.

Discussion: The newly identified rs1461684 G variant associates with sAD risk, rate of disease progression, and gene expression. Contactin 5 protein and mRNA are affected particularly in the early stages of the disease.

Share

CCNA - CCNV white logo

Receive the
latest news

Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.

Illustration of elderly people on a park bench